| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
microRNA 137 | 0.513 | 0.846 |
|
disease | 0.400 | None | 0.954 | 65 | 1 | 2011 | 2020 | |||||||||
|
H3 histone pseudogene 40 | 0.506 | 0.846 |
|
disease | 0.100 | None | 0.952 | 63 | 0 | 1991 | 2020 | |||||||||
|
DAOA antisense RNA 1 | 0.729 | 0.154 |
|
disease | 0.400 | None | 1.000 | 15 | 9 | 2004 | 2014 | |||||||||
|
MIR137 host gene | 0.839 | 0.038 |
|
disease | 0.460 | None | 0.500 | 15 | 6 | 2011 | 2019 | |||||||||
|
disrupted in schizophrenia 2 | 0.716 | 0.192 |
|
disease | 0.500 | None | 1.000 | 11 | 2 | 2001 | 2010 | |||||||||
|
long intergenic non-protein coding RNA 1470 | 0.890 | 0.077 |
|
disease | 0.100 | None | 1.000 | 9 | 8 | 2013 | 2019 | |||||||||
|
synapsin II | 0.653 | 0.577 |
|
disease | 0.490 | None | 0.889 | 9 | 6 | 2000 | 2019 | |||||||||
|
BORCS7-ASMT readthrough (NMD candidate) | 0.805 | 0.154 |
|
disease | 0.100 | None | 1.000 | 8 | 8 | 2011 | 2019 | |||||||||
|
EP300 antisense RNA 1 | 0.839 | 0.231 |
|
disease | 0.100 | None | 1.000 | 8 | 1 | 2014 | 2019 | |||||||||
|
GRM3 antisense RNA 1 | 1.000 | 0.038 |
|
disease | 0.100 | None | 1.000 | 8 | 3 | 2014 | 2019 | |||||||||
|
endogenous retrovirus group W member 1, envelope | 0.505 | 0.692 |
|
disease | 0.370 | None | 1.000 | 8 | 0 | 2008 | 2019 | |||||||||
|
MEF2C antisense RNA 1 | 0.861 | 0.154 |
|
disease | 0.100 | None | 1.000 | 7 | 3 | 2014 | 2019 | |||||||||
|
gulonolactone (L-) oxidase, pseudogene | 0.805 | 0.308 |
|
disease | 0.100 | None | 1.000 | 7 | 4 | 2014 | 2019 | |||||||||
|
BDNF antisense RNA | 0.638 | 0.538 |
|
disease | 0.070 | None | 0.857 | 7 | 9 | 1999 | 2018 | |||||||||
|
MIR29B2 and MIR29C host gene | 0.839 | 0.192 |
|
disease | 0.100 | None | 1.000 | 6 | 2 | 2014 | 2019 | |||||||||
|
actin gamma 1 pseudogene 22 | 0.931 | 0.038 |
|
disease | 0.100 | None | 1.000 | 6 | 2 | 2014 | 2019 | |||||||||
|
centralopathic epilepsy | 0.626 | 0.423 |
|
disease | 0.060 | None | 1.000 | 6 | 0 | 2017 | 2019 | |||||||||
|
long intergenic non-protein coding RNA 2057 | 1.000 | 0.038 |
|
disease | 0.100 | None | 1.000 | 6 | 2 | 2013 | 2019 | |||||||||
|
major histocompatibility complex, class II, DR beta 9 (pseudogene) | 0.682 | 0.654 |
|
disease | 0.100 | None | 1.000 | 6 | 10 | 2011 | 2019 | |||||||||
|
neurofilament light | 0.488 | 0.769 |
|
disease | 0.350 | None | 0.500 | 6 | 0 | 2004 | 2009 | |||||||||
|
long intergenic non-protein coding RNA 2551 | 1.000 | 0.038 |
|
disease | 0.100 | None | 1.000 | 5 | 3 | 2014 | 2019 | |||||||||
|
microRNA 132 | 0.485 | 0.846 |
|
disease | 0.050 | None | 1.000 | 5 | 0 | 2012 | 2018 | |||||||||
|
microRNA 346 | 0.631 | 0.615 |
|
disease | 0.350 | None | 1.000 | 5 | 0 | 2009 | 2017 | |||||||||
|
cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene | 0.805 | 0.346 |
|
disease | 0.100 | None | 1.000 | 5 | 7 | 2015 | 2019 | |||||||||
|
HDAC2 and HS3ST5 antisense RNA 2 | 1.000 | 0.038 |
|
disease | 0.100 | None | 1.000 | 4 | 3 | 2013 | 2019 |